Novel COMT inhibitor opicapone shows sustained inhibition and improved L-DOPA availability in monkeys
Objective: To evaluate the effect of repeated OPC treatments, COMT inhibition versus plasma opicapone level, dose response of COMT inhibition, and systematic and central bioavailability…A single center retrospective analysis of Opicapone treatment in 90 Parkinson patients
Objective: To evaluate retrospectively the treatment with the novel COMT-inhibitor opicapone (OPC) in a tertiary Parkinson Center the first year after its approval in Germany…Deletions at 22q11.2 in idiopathic Parkinson’s disease: A combined analysis of GWAS data
Objective: To verify the reported association of Parkinson's disease(PD) with Chromosome 22q11.2 Deletion Syndrome(22q11.2DS) in series of large, independent idiopathic PD case-control studies. Background: PD…Catechol-o-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson’s disease
Objective: The Catechol-O-Methyltransferase (COMT) Val158Met polymorphism has been proposed to be associated with increased risk of PD and have a specific impact on dopamine-mediated prefrontal…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.